🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

672 results for “Nan” Clear

  1. Dasatinib

    United Therapeutics Europe Ltd

    Malignant Pleural Mesothelioma

    phase 1 small molecule completed

    1 trial

  2. Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy

    Nanjing Legend Biotech Co.

    Lymphoma, B-Cell

    phase 1 small molecule terminated

    1 trial

  3. Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy

    Nanjing Legend Biotech Co.

    Refractory B Acute Lymphoblastic Leukemia

    phase 1 small molecule terminated

    1 trial

  4. EBV immunological agent

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Malignant Tumor

    phase 1 mab active

    1 trial

  5. EDP 305

    ENANTA PHARMACEUTICALS INC

    Presumptive NAFLD

    phase 1 small molecule completed

    1 trial

  6. EDP 305

    ENANTA PHARMACEUTICALS INC

    NASH

    phase 1 small molecule completed

    1 trial

  7. EDP-235

    ENANTA PHARMACEUTICALS INC

    SARS CoV 2 Infection

    phase 1 small molecule completed

    1 trial

  8. EDP-297

    ENANTA PHARMACEUTICALS INC

    NASH - Nonalcoholic Steatohepatitis With Liver Fibrosis

    phase 1 small molecule completed

    1 trial

  9. EDP-305

    ENANTA PHARMACEUTICALS INC

    NASH - Nonalcoholic Steatohepatitis

    phase 1 small molecule completed

    2 trials

  10. EDP-322

    ENANTA PHARMACEUTICALS INC

    MRSA, SSTI

    phase 1 small molecule completed

    1 trial

  11. EDP-322

    ENANTA PHARMACEUTICALS INC

    Skin and Soft Tissue Infections

    phase 1 small molecule completed

    1 trial

  12. EDP-323

    ENANTA PHARMACEUTICALS INC

    RSV Infection

    phase 1 small molecule completed

    3 trials

  13. EDP-494

    ENANTA PHARMACEUTICALS INC

    Hepatitis C

    phase 1 small molecule completed

    1 trial

  14. EDP-514

    ENANTA PHARMACEUTICALS INC

    Chronic HBV Infection

    phase 1 small molecule completed

    2 trials

  15. EDP-514

    ENANTA PHARMACEUTICALS INC

    Hepatitis B

    phase 1 small molecule completed

    1 trial

  16. EDP-721

    ENANTA PHARMACEUTICALS INC

    Chronic Hepatitis B Virus Infection

    phase 1 small molecule terminated

    1 trial

  17. EDP-788

    ENANTA PHARMACEUTICALS INC

    Healthy

    phase 1 small molecule terminated

    1 trial

  18. EDP-788

    ENANTA PHARMACEUTICALS INC

    Safety in Normal Volunteers

    phase 1 small molecule completed

    1 trial

  19. EDP-978

    ENANTA PHARMACEUTICALS INC

    Chronic Inducible Urticaria

    phase 1 small molecule active

    1 trial

  20. EDP239

    ENANTA PHARMACEUTICALS INC

    Hepatitis C

    phase 1 small molecule completed

    1 trial

  21. ENMD-2076

    CASI Pharmaceuticals

    Relapsed or Refractory Hematological Malignancies

    phase 1 small molecule completed

    1 trial

  22. EXS73565

    RECURSION PHARMACEUTICALS, INC.

    Relapsed or Refractory B-cell Malignancies

    phase 1 small molecule active

    1 trial

  23. Efficacy of LCAR-T2C CAR-T cells

    Nanjing Legend Biotech Co.

    T Cell Lymphoma

    phase 1 small molecule terminated

    1 trial

  24. Efficacy of LCAR-T2C CAR-T cells

    Nanjing Legend Biotech Co.

    CD4+ T Lymphocyte Tumor (T Cell Lymphoma and T Cell Leukemia)

    phase 1 small molecule terminated

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources